Lemonex

Pipeline

Lemonex is developing cancer immunotherapeutics, antibody therapeutics and gene therapeutics based on next-generation innovative
modular drug delivery technology and biosensor technology. We especially focus on the development of therapeutics to treat cancers,
intractable diseases

Cancer Immunotherapy & Targeted Cancer Therapy

Pipeline	Type	Indication	Research	Pre-clinical	Clinical Phase
Pipeline	Type	Indication	Research	Pre-clinical	Ⅰ	Ⅱ	Ⅲ
LEM-TA201	Nanobio-Robot	HCC	●	●	○
LEM-AB701M	Antibody	Solid Tumor	●	●	○	○	○
LEM-AB702M	Cytokine	Solid Tumor	●	●	○	○	○
LEM-AB703M	Antibody + Cytokine	Solid Tumor	●	○	○	○	○
LEM-AB801M	mRNA	Solid Tumor	●	●	○	○	○
LEM-OT501	Synthetic Drug	Gynecologic cancer	●	○	○	○	○

Intractable Diseases

Pipeline	Type	Indication	Research	Pre-clinical	Clinical Phase
Pipeline	Type	Indication	Research	Pre-clinical	Ⅰ	Ⅱ	Ⅲ
LEM-S401M	siRNA	Atopic Dermatitis	●	●	○	○	○
LEM-S402M	siRNA	Hypertrophic scar	●	●	○	○	○

Lemonex Inc. | Address : Bldg. #220-630 Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
CEO : Cheolhee Won, CTO : Dal-Hee Min | Tel : +82-2-875-7797 | Fax : +82-2-882-7798 | E-mail : info@lemonexbio.com
Copyright (c) 2018 Lemonex Inc., All rights reserved.